Hadha is a potential predictor of response to platinum-based chemotherapy for lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 12, 2011, Pages 3457-3463

  Kageyama, Taihei ^a   Nagashio, Ryo ^a   Ryuge, Shinichiro ^a   Matsumoto, Toshihide ^a   Iyoda, Akira ^a   Satoh, Yukitoshi ^a   Masuda, Noriyuki ^a   Jiang, Shi Xu ^a   Saegusa, Makoto ^a   Sato, Yuichi ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Cisplatin; Dimensional gel electrophoresis; Hadha; Lung cancer; Two

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; ETOPOSIDE; FATTY ACID BETA OXIDATION MULTIENZYME COMPLEX; FATTY ACID BETA-OXIDATION MULTIENZYME COMPLEX; GEMCITABINE; IRINOTECAN; MULTIENZYME COMPLEX; PACLITAXEL;

ADENOCARCINOMA; ARTICLE; ENZYMOLOGY; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TUMOR; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR CELL CULTURE; TUMOR RECURRENCE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ETOPOSIDE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MULTIENZYME COMPLEXES; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED;

EID: 84864517874     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Aggarwal S, He T, Moore PA, et al (2009). Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer. Gynecol Oncol, 115, 430-7.
2. Andrews PA, Albright KD (1992). Mitochondrial defects in cis-Diamminedichloroplatinum (II) resistant human ovarian carcinoma cells. Cancer Res, 52, 1895-901.
3. Baldwin G S, Murphy V J, Yang Z, Hashimoto T (1998). Binding of nonsteroidal anti-inflammatory drugs to the alpha-subunit of the trifunctional protein of long chain fatty acid oxidation. JPET, 286, 1110-4.
4. Carew JS, Zhou Y, Keating MJ, et al (2003). Mitochondrial DNAmutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia, 17, 1437-47.
5. Cheng YJ, Jiang HS, Hsueh CM, et al (2010). XIAP-mediated protection of H460 lung cancer cells against cisplatin. Eur J Pharmacol, 627, 75-84.
6. Cicchillitti L, Michele M, Rotilio D, et al (2009). Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell lines and its resistant counterpart A2780TC1 by 2D-DIGE: The role of ERp57. J Proteome Res, 8, 1902-12.
7. Conklin KA (2002). Dietary polyunsaturated fatty acids: Impact on cancer chemotherapy and radiation. Altern Med Rev, 7, 4-21.
8. Gonzalez V M, Fuertes M A, Alonso C, Perez J M (2001). Is cisplatin-induced cell death always producted by apoptosis?, Mol Pharmacol, 59, 657-63.
9. Jemal A Siegel R, Thun M J, et al (2009). Cancer statistics, 2009 CA. Cancer J Clin, 59, 225-49.
10. Jiang SX, Kameya T, Okayasu I, et al (2004). hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod Pathol, 17, 222-9.
11. Kamijo T, Wanders RJA, Komiyama A, et al (1994). Mitochondrial trifunctional protein deficiency. J Clin Invest, 93, 1740-7.
12. Kim S Y, Lee S W, Lee S C, et al (2009). Proteomic analysis of liver tissue from HBx-transgenic mice at early stage of hepatocarcinogenesis. Proteomics, 9, 5056-66.
13. Lee DH, Chung K, An HJ, et al (2010). Proteomic Identification of palitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells. J Proteome Res, 9, 5668-76.
14. Michele MD, Corte AD, Rotilio D, et al (2009). A proteomic approach to palitaxel chemoresistance in ovarian cancer cell lines. Biochem Biophys Acta, 1794, 225-36.
15. Mizutani S, Miyato Y, Tokunaga A, et al (2009). Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs. Cancer Sci, 100, 1680-7.
16. Murphy RA, Mourtzakis M, Reiman T, et al (2011). Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer, 10, 1002/cncr.25933, in press.
17. Nagashio R, Sato Y, Okayasu I, et al (2010). Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas. Pathol Inter, 60, 71-7.
18. Oh-Ishi M, Satoh M, Maeda T (2000). Preparative two-dimension gel electrophoresis with agarose gels in the first dimension for high molecular mass proteins. Electrophoresis, 21, 1653-69.
19. Pepe C, Hasan B, Shepherd F A, et al (2007). Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol, 25, 1553-61.
20. Qian W, Nishikawa M, Mashimo M, et al (2005). Mitochondria density determines the cellular sensitivity to cisplatin-induced cell death. Am J Physiol Cell Physiol, 289, 1466-75.
21. Shidara Y, Yamagata K, Ohta S, et al (2005). Positive contribution of pathogenic mutation in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res, 65, 1655-63.
22. Stewart DJ (2007). Mechanism of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol, 63, 12-31.
23. Timmer-Bossacha H, Hospers GA, Martini IA, et al (1989). Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst 1989, 81, 1069-75.
24. Uchida Y, Izai K, Orii T, Hashimoto T (1992). Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. J Biol Chem, 267, 1034-41.
25. Urbani A, Poland J, Federici G, et al (2005). A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics, 5, 796-804.
26. Xu X, Qiao M, Shi Q, et al (2010). Quantitative proteomics study of breast cancer cell lines isolated from a single patient: Discovery of TIMM17A as a marker for breast cancer. Proteomics, 10, 1374-90.